Many groups have developed mAbs aimed at targeting costimulatory molecules involved in T-cell activation, resulting in GVHD protection in murine models (25), but some of them, such as anti-OX-40 and anti-4-1BB, have also altered GVL reaction (26, 27). This evidence concerns the gene TNFRSF4 and graft versus host disease.